|
000
| 02384nam 2200433zi 4500 |
|---|
| 001 | 9.914493 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20230120085522 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 220816e20220819onc ob f000 0 eng d |
|---|
| 020 | |a9780660450681|q(report) |
|---|
| 020 | |a9780660450698|q(summary) |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP5-141/1-2022E-PDF |
|---|
| 086 | 1 |aHP5-141/2-2022E-PDF |
|---|
| 245 | 00|aRecommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age. |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cAugust 19, 2022. |
|---|
| 264 | 4|c©2022 |
|---|
| 300 | |a1 online resource (17 pages) + |e1 summary (5 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Recommandations sur l'utilisation d'une première dose de rappel du vaccin Comirnaty de Pfizer-BioNTech contre la COVID-19 chez les les enfants de 5 à 11 ans. |
|---|
| 500 | |aAt head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). |
|---|
| 504 | |aIncludes bibliographical references (pages 14-17). |
|---|
| 650 | 0|aCOVID-19 vaccines|zCanada. |
|---|
| 650 | 0|aCOVID-19 (Disease)|xVaccination|zCanada. |
|---|
| 650 | 0|aVaccination of children|zCanada. |
|---|
| 650 | 0|aCOVID-19 vaccines|xGovernment policy|zCanada. |
|---|
| 650 | 0|aCOVID-19 (Disease)|xVaccination|xGovernment policy|zCanada. |
|---|
| 650 | 0|aVaccination of children|xGovernment policy|zCanada. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 775 | 08|tRecommandations sur l'utilisation d'une première dose de rappel du vaccin Comirnaty de Pfizer-BioNTech contre la COVID-19 chez les les enfants de 5 à 11 ans.|w(CaOODSP)9.914494 |
|---|
| 794 | |tUpdated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration.|w(CaOODSP)9.917987 |
|---|
| 856 | 40|qPDF|s928 KB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-141-1-2022-eng.pdf|z(report) |
|---|
| 856 | 40|qPDF|s954 KB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP5-141-2-2022-eng.pdf|z(summary) |
|---|